Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

SapM mutation to improve the BCG vaccine: genomic, transcriptomic and preclinical safety characterization

2018

The Mycobacterium bovis Bacille Calmette Guerin (BCG) vaccine shows variable efficacy in protection against adult tuberculosis (TB). Earlier, we have described a BCG mutant vaccine with a transposon insertion in the gene coding for the secreted acid phosphatase SapM, which led to enhanced long-term survival of vaccinated mice challenged with TB infection. To facilitate development of this mutation as part of a future improved live attenuated TB vaccine, we have now characterized the genome and transcriptome of this sapM::Tn mutant versus parental BCG Pasteur. Furthermore, we show that the sapM::Tn mutant had an equal low pathogenicity as WT BCG upon intravenous administration to immunocompromised SCID mice, passing this important safety test. Subsequently, we investigated the clearance of this improved vaccine strain following vaccination and found a more effective innate immune control over the sapM::Tn vaccine bacteria as compared to WT BCG. This leads to a fast contraction of IFN...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.